MX389683B - Composiciones terapeuticas, combinaciones y metodos de uso - Google Patents

Composiciones terapeuticas, combinaciones y metodos de uso

Info

Publication number
MX389683B
MX389683B MX2018000288A MX2018000288A MX389683B MX 389683 B MX389683 B MX 389683B MX 2018000288 A MX2018000288 A MX 2018000288A MX 2018000288 A MX2018000288 A MX 2018000288A MX 389683 B MX389683 B MX 389683B
Authority
MX
Mexico
Prior art keywords
methods
combinations
therapeutic compositions
mammals
administering
Prior art date
Application number
MX2018000288A
Other languages
English (en)
Other versions
MX2018000288A (es
Inventor
David T Weaver
Jennifer E Ring
Jonathan A Pachter
Yan Wang
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of MX2018000288A publication Critical patent/MX2018000288A/es
Publication of MX389683B publication Critical patent/MX389683B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención se refiere a métodos que comprenden administrar un inhibidor de FAK y un agente inmunoterapéutico tal como anti-PD-1 o anti-PD-L1; que son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en mamíferos, especialmente en humanos.
MX2018000288A 2015-06-29 2016-06-29 Composiciones terapeuticas, combinaciones y metodos de uso MX389683B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186197P 2015-06-29 2015-06-29
PCT/US2016/040080 WO2017004192A1 (en) 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use

Publications (2)

Publication Number Publication Date
MX2018000288A MX2018000288A (es) 2018-11-09
MX389683B true MX389683B (es) 2025-03-20

Family

ID=57609144

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000288A MX389683B (es) 2015-06-29 2016-06-29 Composiciones terapeuticas, combinaciones y metodos de uso
MX2022001165A MX2022001165A (es) 2015-06-29 2018-01-08 Composiciones terapeuticas, combinaciones y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001165A MX2022001165A (es) 2015-06-29 2018-01-08 Composiciones terapeuticas, combinaciones y metodos de uso.

Country Status (13)

Country Link
US (3) US10532056B2 (es)
EP (2) EP3313404B1 (es)
JP (3) JP2018519327A (es)
KR (1) KR102783581B1 (es)
CN (2) CN108289892B (es)
AU (3) AU2016286091B2 (es)
CA (2) CA3244408A1 (es)
EA (1) EA201890161A1 (es)
ES (1) ES2987376T3 (es)
IL (2) IL322086A (es)
MX (2) MX389683B (es)
WO (1) WO2017004192A1 (es)
ZA (1) ZA201800572B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PT3023100T (pt) 2013-07-18 2019-05-29 Taiho Pharmaceutical Co Ltd Fármaco antitumoral para administração intermitente de inibidor de fgfr
MX384259B (es) * 2014-01-09 2025-03-14 Verastem Inc Composiciones y metodos para tratamiento de crecimiento celular anormal.
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN117567535A (zh) 2015-09-10 2024-02-20 坦伯公司 生物正交组合物
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4039260B1 (en) * 2017-02-07 2024-04-17 Saitama Medical University Cd62llow cd4+ t-cells for treating or preventing cancer
WO2018187740A1 (en) 2017-04-07 2018-10-11 Shasqi, Inc. Bioorthogonal compositions
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2019018666A1 (en) * 2017-07-21 2019-01-24 University Of North Dakota INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES
EP3765085A1 (en) * 2018-03-12 2021-01-20 Université de Paris Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
MX2020009762A (es) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Composicion farmaceutica que incluye alquil sulfato de sodio.
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
CN111377871B (zh) * 2018-12-27 2021-03-19 海创药业股份有限公司 一种fak抑制剂及其联合用药物
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
WO2020171138A1 (ja) 2019-02-20 2020-08-27 学校法人 埼玉医科大学 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
US20220184082A1 (en) * 2019-02-28 2022-06-16 Taiho Pharmaceutical Co., Ltd. Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
TWI757716B (zh) * 2019-04-15 2022-03-11 禾榮科技股份有限公司 微創型中子束產生裝置及微創型中子捕獲治療系統
JP7199523B2 (ja) 2019-05-10 2023-01-05 富士フイルム株式会社 光照射装置およびセンサー
CN110201171A (zh) * 2019-06-18 2019-09-06 北京大学 Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用
EP3986426A4 (en) * 2019-06-21 2023-10-18 Board of Regents, The University of Texas System TARGETING ALPHA3BETA1 INTEGRIN TO TREAT CANCER AND OTHER DISEASES
CA3145889A1 (en) * 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
KR20220101677A (ko) 2019-11-18 2022-07-19 인엑스메드 (난징) 컴퍼니 리미티드 Nras 돌연변이를 갖는 종양을 치료하기 위한 약물의 제조에서의 fak 억제제의 용도
MY209389A (en) * 2019-11-28 2025-07-07 Inxmed Nanjing Co Ltd Use of bi853520 in cancer treatment
CN115279376A (zh) * 2020-01-31 2022-11-01 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
EP4101453A4 (en) * 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
JP7470775B2 (ja) 2020-02-14 2024-04-18 富士フイルム株式会社 光結合システムおよび光通信デバイス
IL299789A (en) * 2020-07-13 2023-03-01 Verastem Inc Combinations of MEK/RAF suppressor and anti-1-PD antibody for cancer therapy
EP4259659A4 (en) * 2020-12-08 2025-02-12 Cornell University METHODS FOR INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE
KR20240028325A (ko) * 2020-12-11 2024-03-05 매터리어 테라퓨틱스 인크. 체크포인트 억제제와 조합하여 보센탄을 사용하는 암 치료
WO2023020291A1 (zh) 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 In10018与pld的联用
TW202339755A (zh) * 2021-12-10 2023-10-16 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
JP2025520715A (ja) * 2022-06-24 2025-07-03 ▲應▼世生物科技（南京）有限公司 腫瘍を処置するための組合せ医薬及びその使用
EP4578449A4 (en) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE
JP2025528528A (ja) * 2022-09-05 2025-08-28 ▲應▼世生物科技（南京）有限公司 Ｆａｋ阻害剤及びｅｇｆｒ－ｔｋｉの薬学的組合せ及び使用
TW202412766A (zh) * 2022-09-16 2024-04-01 大陸商應世生物科技（南京）有限公司 Ｆａｋ抑制劑及拓撲異構酶抑制劑的藥物組合及用途
KR20250078507A (ko) * 2022-09-30 2025-06-02 인엑스메드 (난징) 컴퍼니 리미티드 Fak 억제제와 면역원성 세포 사멸 유도 물질의 약제학적 병용물 및 이의 용도
WO2024158840A2 (en) * 2023-01-24 2024-08-02 Simcha IL-18, Inc. Methods and compositions for combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
FI20030976L (fi) 2003-06-30 2004-12-31 M Real Oyj Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi
EP1761132B1 (en) 2004-06-30 2011-11-23 Cadbury Holdings Limited Chewing gum comprising flavor emulsion
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
JP5569956B2 (ja) 2007-03-16 2014-08-13 ザ スクリプス リサーチ インスティテュート 接着斑キナーゼのインヒビター
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
US20100317663A1 (en) 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
CN102124000B (zh) 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2013003575A1 (en) * 2011-06-28 2013-01-03 Glaxosmithkline Llc Method of administration and treatment
HK1214128A1 (zh) * 2012-10-05 2016-07-22 Bluelink Pharmaceuticals, Inc. 癌症的治療
US20150118247A1 (en) * 2013-10-25 2015-04-30 Nodality, Inc. Methods and compositions for immunomodulation
CA2928908C (en) * 2013-11-01 2021-01-12 Pfizer Inc. Vectors for expression of prostate-associated antigens
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
WO2017201043A1 (en) 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer

Also Published As

Publication number Publication date
AU2021202379B2 (en) 2023-05-11
CA2991044C (en) 2024-11-19
AU2021202379A1 (en) 2021-05-13
WO2017004192A1 (en) 2017-01-05
NZ739490A (en) 2024-11-29
ZA201800572B (en) 2023-12-20
EA201890161A1 (ru) 2018-06-29
KR102783581B1 (ko) 2025-03-17
MX2022001165A (es) 2022-02-22
ES2987376T3 (es) 2024-11-14
US10532056B2 (en) 2020-01-14
NZ777396A (en) 2025-03-28
CA2991044A1 (en) 2017-01-05
EP3313404B1 (en) 2024-09-04
IL256652A (en) 2018-02-28
US11564927B2 (en) 2023-01-31
CN108289892B (zh) 2021-11-23
EP3313404A4 (en) 2019-08-07
JP2024111247A (ja) 2024-08-16
CA3244408A1 (en) 2025-06-13
US20180177788A1 (en) 2018-06-28
JP2018519327A (ja) 2018-07-19
IL322086A (en) 2025-09-01
US20240000790A1 (en) 2024-01-04
AU2023214272A1 (en) 2023-08-31
AU2016286091B2 (en) 2021-02-04
CN114209841A (zh) 2022-03-22
IL256652B1 (en) 2025-11-01
CN108289892A (zh) 2018-07-17
AU2023214272B2 (en) 2025-08-14
BR112017028519A2 (en) 2018-08-28
JP2021183650A (ja) 2021-12-02
EP3313404C0 (en) 2024-09-04
KR20180100539A (ko) 2018-09-11
HK1254525A1 (en) 2019-07-19
EP4488265A2 (en) 2025-01-08
EP3313404A1 (en) 2018-05-02
MX2018000288A (es) 2018-11-09
US20200330471A1 (en) 2020-10-22
EP4488265A3 (en) 2025-04-02
AU2016286091A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
SV2018005787A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
CL2018001052A1 (es) Péptidos y peptidomiméticos en combinación con agentes activadores de células t y/o inhibidores de puntos de control para el tratamiento del cáncer
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
AU2016323967A8 (en) Compositions and methods for the treatment and prevention of radiation dermatitis